Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pierre Fenaux

Showing results (1-10 of 432) with videos related to

Pageof 44
Sort By:
Seminars in Hematology|June 11, 2004
Myelodysplastic syndromes: From pathogenesis and prognosis to treatmentPierre Fenaux
Nature Clinical Practice. Oncology|December 13, 2005
Inhibitors of DNA methylation: beyond myelodysplastic syndromesPierre Fenaux
Seminars in Oncology|August 9, 2005
Response assessments in low-risk and high-risk myelodysplastic syndromes (MDS)Pierre Fenaux
International Journal of Hematology|August 16, 2001
Chromosome and molecular abnormalities in myelodysplastic syndromesPierre Fenaux
Blood|April 12, 2013
How we treat lower-risk myelodysplastic syndromesPierre Fenaux, Lionel Adès
Leukemia Research|December 17, 2009
Review of azacitidine trials in Intermediate-2-and High-risk myelodysplastic syndromesPierre Fenaux, Lionel Ades
Best Practice & Research. Clinical Haematology|February 11, 2014
Myelodysplastic Syndromes (MDS) and autoimmune disorders (AD): cause or consequence?Thorsten Braun, Pierre Fenaux
Reviews in Clinical and Experimental Hematology|July 20, 2005
Supportive care including growth factors in myelodysplastic syndromesClaude Gardin, Pierre Fenaux
Current Hematologic Malignancy Reports|April 29, 2010
Is cytarabine required in the treatment of acute promyelocytic leukemia?Lionel Adès, Pierre Fenaux
Current Opinion in Hematology|January 18, 2012
Optimizing hypomethylating agents in myelodysplastic syndromesRaphael Itzykson, Pierre Fenaux
Pageof 44

Showing results (1-10 of 432) with videos related to

Sort By:
Pageof 44
Seminars in Hematology|June 11, 2004
Myelodysplastic syndromes: From pathogenesis and prognosis to treatmentPierre Fenaux
Nature Clinical Practice. Oncology|December 13, 2005
Inhibitors of DNA methylation: beyond myelodysplastic syndromesPierre Fenaux
Seminars in Oncology|August 9, 2005
Response assessments in low-risk and high-risk myelodysplastic syndromes (MDS)Pierre Fenaux
International Journal of Hematology|August 16, 2001
Chromosome and molecular abnormalities in myelodysplastic syndromesPierre Fenaux
Blood|April 12, 2013
How we treat lower-risk myelodysplastic syndromesPierre Fenaux, Lionel Adès
Leukemia Research|December 17, 2009
Review of azacitidine trials in Intermediate-2-and High-risk myelodysplastic syndromesPierre Fenaux, Lionel Ades
Best Practice & Research. Clinical Haematology|February 11, 2014
Myelodysplastic Syndromes (MDS) and autoimmune disorders (AD): cause or consequence?Thorsten Braun, Pierre Fenaux
Reviews in Clinical and Experimental Hematology|July 20, 2005
Supportive care including growth factors in myelodysplastic syndromesClaude Gardin, Pierre Fenaux
Current Hematologic Malignancy Reports|April 29, 2010
Is cytarabine required in the treatment of acute promyelocytic leukemia?Lionel Adès, Pierre Fenaux
Current Opinion in Hematology|January 18, 2012
Optimizing hypomethylating agents in myelodysplastic syndromesRaphael Itzykson, Pierre Fenaux
Pageof 44